U.S. Markets

Eli Lilly (LLY) has entered into a deal with Ascidian worth up to USD 1.9bln to develop treatments for inherited kidney diseases

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more